Logo image of MGLN

MAGELLAN HEALTH INC (MGLN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MGLN - Common Stock

94.99
0 (0%)
Last: 1/3/2022, 8:23:03 PM
94.99
0 (0%)
After Hours: 1/3/2022, 8:23:03 PM
Fundamental Rating

2

Overall MGLN gets a fundamental rating of 2 out of 10. We evaluated MGLN against 100 industry peers in the Health Care Providers & Services industry. While MGLN seems to be doing ok healthwise, there are quite some concerns on its profitability. MGLN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MGLN was profitable.
MGLN Yearly Net Income VS EBIT VS OCF VS FCFMGLN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 100M 200M 300M

1.2 Ratios

Industry RankSector Rank
ROA 9%
ROE 15.61%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGLN Yearly ROA, ROE, ROICMGLN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 5 10 15 20

1.3 Margins

Industry RankSector Rank
OM 1.03%
PM (TTM) 6.26%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGLN Yearly Profit, Operating, Gross MarginsMGLN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2 4 6 8

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for MGLN has been increased compared to 1 year ago.
MGLN has a better debt/assets ratio than last year.
MGLN Yearly Shares OutstandingMGLN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
MGLN Yearly Total Debt VS Total AssetsMGLN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 1B 2B 3B

2.2 Solvency

An Altman-Z score of 3.80 indicates that MGLN is not in any danger for bankruptcy at the moment.
MGLN has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 3.8
ROIC/WACCN/A
WACCN/A
MGLN Yearly LT Debt VS Equity VS FCFMGLN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 500M 1B 1.5B

2.3 Liquidity

MGLN has a Current Ratio of 2.92. This indicates that MGLN is financially healthy and has no problem in meeting its short term obligations.
MGLN has a Quick Ratio of 2.86. This indicates that MGLN is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.86
MGLN Yearly Current Assets VS Current LiabilitesMGLN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 500M 1B 1.5B 2B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for MGLN have decreased strongly by -67.07% in the last year.
MGLN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.05% yearly.
Looking at the last year, MGLN shows a small growth in Revenue. The Revenue has grown by 6.52% in the last year.
MGLN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.09% yearly.
EPS 1Y (TTM)-67.07%
EPS 3Y-32.6%
EPS 5Y6.05%
EPS Q2Q%-62.5%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y-7.79%
Revenue growth 5Y-0.09%
Sales Q2Q%7.18%

3.2 Future

Based on estimates for the next years, MGLN will show a very strong growth in Earnings Per Share. The EPS will grow by 42.68% on average per year.
The Revenue is expected to grow by 7.97% on average over the next years.
EPS Next Y11.05%
EPS Next 2Y43.46%
EPS Next 3Y36.35%
EPS Next 5Y42.68%
Revenue Next Year8.27%
Revenue Next 2Y8.12%
Revenue Next 3Y8.38%
Revenue Next 5Y7.97%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MGLN Yearly Revenue VS EstimatesMGLN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B
MGLN Yearly EPS VS EstimatesMGLN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MGLN is valuated quite expensively with a Price/Earnings ratio of 87.15.
MGLN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.49.
The Price/Forward Earnings ratio is 27.31, which means the current valuation is very expensive for MGLN.
The average S&P500 Price/Forward Earnings ratio is at 23.69. MGLN is around the same levels.
Industry RankSector Rank
PE 87.15
Fwd PE 27.31
MGLN Price Earnings VS Forward Price EarningsMGLN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.26
MGLN Per share dataMGLN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates MGLN does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as MGLN's earnings are expected to grow with 36.35% in the coming years.
PEG (NY)7.88
PEG (5Y)14.41
EPS Next 2Y43.46%
EPS Next 3Y36.35%

More info and screens

0

5. Dividend

5.1 Amount

MGLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MAGELLAN HEALTH INC

NASDAQ:MGLN (1/3/2022, 8:23:03 PM)

After market: 94.99 0 (0%)

94.99

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)03-04 2022-03-04/amc
Inst Owners1.27%
Inst Owner Change0%
Ins Owners1.57%
Ins Owner Change0%
Market Cap2.46B
Revenue(TTM)4.82B
Net Income(TTM)301.97M
Analysts43.33
Price Target96.9 (2.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 87.15
Fwd PE 27.31
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB N/A
EV/EBITDA 12.26
EPS(TTM)1.09
EY1.15%
EPS(NY)3.48
Fwd EY3.66%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS186.23
BVpS74.7
TBVpSN/A
PEG (NY)7.88
PEG (5Y)14.41
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 9%
ROE 15.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 1.03%
PM (TTM) 6.26%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.44
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.86
Altman-Z 3.8
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-67.07%
EPS 3Y-32.6%
EPS 5Y6.05%
EPS Q2Q%-62.5%
EPS Next Y11.05%
EPS Next 2Y43.46%
EPS Next 3Y36.35%
EPS Next 5Y42.68%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y-7.79%
Revenue growth 5Y-0.09%
Sales Q2Q%7.18%
Revenue Next Year8.27%
Revenue Next 2Y8.12%
Revenue Next 3Y8.38%
Revenue Next 5Y7.97%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

MAGELLAN HEALTH INC / MGLN FAQ

Can you provide the ChartMill fundamental rating for MAGELLAN HEALTH INC?

ChartMill assigns a fundamental rating of 5 / 10 to MGLN.


What is the valuation status of MAGELLAN HEALTH INC (MGLN) stock?

ChartMill assigns a valuation rating of 2 / 10 to MAGELLAN HEALTH INC (MGLN). This can be considered as Overvalued.


Can you provide the profitability details for MAGELLAN HEALTH INC?

MAGELLAN HEALTH INC (MGLN) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for MGLN stock?

The Price/Earnings (PE) ratio for MAGELLAN HEALTH INC (MGLN) is 87.15 and the Price/Book (PB) ratio is 1.27.


What is the financial health of MAGELLAN HEALTH INC (MGLN) stock?

The financial health rating of MAGELLAN HEALTH INC (MGLN) is 7 / 10.